Novartis | NVS - Gewinn Vor Steuern

Aktienkurs
143.01
Täglich Wechseln
-2.43 -1.67%
Monatlich
-4.90%
Jährlich
26.22%
Q2 Prognose
142.62




Gewinn Vor Steuern Veränderung Datum
AbbVie USD 2.67B 1.71B 2025-12
Amgen USD 3.92B 2.35B 2025-09
AstraZeneca USD 2.63B 615M 2025-12
Bausch Health Companies USD 56M 162M 2025-12
Biogen USD -56M 613.3M 2025-12
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Canopy Growth CAD -62.26M 60.84M 2025-12
Corcept Therapeutics USD 15.24M 16.45M 2025-09
Drreddys Laboratories INR 15.43B 1.96B 2025-12
Eli Lilly USD 7.23B 456M 2025-09
Gilead Sciences USD 2.08B 1.56B 2025-12
GlaxoSmithKline GBP 1.23B 1.23B 2025-12
Glaxosmithkline GBP 2.46B 569M 2025-09
J&J USD 7.82B 2.86B 2026-03
Merck USD 6.74B 22M 2025-09
Novartis USD 4.64B 445M 2025-12
Novartis USD 5.17B 637M 2025-09
Pacira USD 9.52M 11.45M 2025-09
Perrigo USD 22.4M 19.2M 2025-09
Pfizer USD 3.33B 290M 2025-09
Phibro Animal Health USD 38.62M 1.26M 2025-12
Prestige Brands USD 69.13M 7.35M 2025-09
Roche Holding CHF 4.79B 3.01B 2025-06
Sanofi EUR -1.16B 5.5B 2025-12
Sanofi EUR -1.16B 6.23B 2025-12
Supernus Pharmaceuticals USD -1.91M 56.04M 2025-12
Zoetis USD 887M 15M 2025-09